HomeCompareHMAC vs ABBV

HMAC vs ABBV: Dividend Comparison 2026

HMAC yields 34.19% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HMAC wins by $65.7K in total portfolio value
10 years
HMAC
HMAC
● Live price
34.19%
Share price
$5.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$168.1K
Annual income
$24,882.33
Full HMAC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HMAC vs ABBV

📍 HMAC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHMACABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HMAC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HMAC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HMAC
Annual income on $10K today (after 15% tax)
$2,905.98/yr
After 10yr DRIP, annual income (after tax)
$21,149.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HMAC beats the other by $93.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HMAC + ABBV for your $10,000?

HMAC: 50%ABBV: 50%
100% ABBV50/50100% HMAC
Portfolio after 10yr
$135.2K
Annual income
$24,827.04/yr
Blended yield
18.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HMAC
No analyst data
Altman Z
13.0
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HMAC buys
0
ABBV buys
0
No recent congressional trades found for HMAC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHMACABBV
Forward yield34.19%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$168.1K$102.3K
Annual income after 10y$24,882.33$24,771.77
Total dividends collected$120.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HMAC vs ABBV ($10,000, DRIP)

YearHMAC PortfolioHMAC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,119$3,418.80$11,550$430.00+$2.6KHMAC
2$19,618$4,511.16$13,472$627.96+$6.1KHMAC
3$26,850$5,858.24$15,906$926.08+$10.9KHMAC
4$36,222$7,493.14$19,071$1,382.55+$17.2KHMAC
5$48,205$9,447.49$23,302$2,095.81+$24.9KHMAC
6$63,330$11,750.38$29,150$3,237.93+$34.2KHMAC
7$82,191$14,427.22$37,536$5,121.41+$44.7KHMAC
8$105,443$17,498.86$50,079$8,338.38+$55.4KHMAC
9$133,805$20,980.74$69,753$14,065.80+$64.1KHMAC
10$168,053$24,882.33$102,337$24,771.77+$65.7KHMAC

HMAC vs ABBV: Complete Analysis 2026

HMACStock

Hainan Manaslu Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. The company was founded in 2021 and is based in Haikou, China.

Full HMAC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HMAC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HMAC vs SCHDHMAC vs JEPIHMAC vs OHMAC vs KOHMAC vs MAINHMAC vs JNJHMAC vs MRKHMAC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.